BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 35725806)

  • 1. Plasma Profile of Immune Determinants Predicts Pathological Complete Response in Locally Advanced Breast Cancer Patients: A Pilot Study.
    Miceli R; Cao C; Maolanon NN; Jacobs R; Wu J; Orlandi R
    Clin Breast Cancer; 2022 Oct; 22(7):705-714. PubMed ID: 35725806
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum Tumor Marker Levels might have Little Significance in Evaluating Neoadjuvant Treatment Response in Locally Advanced Breast Cancer.
    Wang YJ; Huang XY; Mo M; Li JW; Jia XQ; Shao ZM; Shen ZZ; Wu J; Liu GY
    Asian Pac J Cancer Prev; 2015; 16(11):4603-8. PubMed ID: 26107211
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A prognostic model based on combining estrogen receptor expression and Ki-67 value after neoadjuvant chemotherapy predicts clinical outcome in locally advanced breast cancer: extension and analysis of a previously reported cohort of patients.
    Miglietta L; Morabito F; Provinciali N; Canobbio L; Meszaros P; Naso C; Murialdo R; Boitano M; Salvi S; Ferrarini M
    Eur J Surg Oncol; 2013 Oct; 39(10):1046-52. PubMed ID: 23890870
    [TBL] [Abstract][Full Text] [Related]  

  • 4. LncRNA BCAR4 expression predicts the clinical response to neoadjuvant chemotherapy in patients with locally advanced breast cancer.
    Gan FJ; Li Y; Xu MX; Zhou T; Wu S; Hu K; Li Y; Sun SH; Luo Q
    Cancer Biomark; 2021; 32(3):339-351. PubMed ID: 34151842
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-circulating Tie2 Is Associated With Pathologic Complete Response to Chemotherapy and Antiangiogenic Therapy in Breast Cancer.
    Makhoul I; Griffin RJ; Siegel E; Lee J; Dhakal I; Raj V; Jamshidi-Parsian A; Klimberg S; Hutchins LF; Kadlubar S
    Am J Clin Oncol; 2016 Jun; 39(3):248-54. PubMed ID: 24577164
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of vascular endothelial growth factor and proliferation marker MIB1 are influenced by neoadjuvant chemotherapy in locally advanced breast cancer.
    Singh M; Capocelli KE; Marks JL; Schleicher RB; Finlayson CA; Seligman PA
    Appl Immunohistochem Mol Morphol; 2005 Jun; 13(2):147-56. PubMed ID: 15894927
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ki-67 labeling index as a predictor of response to neoadjuvant chemotherapy in breast cancer.
    Jain P; Doval DC; Batra U; Goyal P; Bothra SJ; Agarwal C; Choudhary DK; Yadav A; Koyalla VPB; Sharma M; Dash P; Talwar V
    Jpn J Clin Oncol; 2019 Apr; 49(4):329-338. PubMed ID: 30753543
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The importance of stromal and intratumoral tumor lymphocyte infiltration for pathologic complete response in patients with locally advanced breast cancer.
    Eryilmaz MK; Mutlu H; Ünal B; Salim DK; Musri FY; Coşkun HŞ
    J Cancer Res Ther; 2018; 14(3):619-624. PubMed ID: 29893329
    [TBL] [Abstract][Full Text] [Related]  

  • 9. EarlyR signature predicts response to neoadjuvant chemotherapy in breast cancer.
    Buechler SA; Gökmen-Polar Y; Badve SS
    Breast; 2019 Feb; 43():74-80. PubMed ID: 30502641
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pathological predictive factors for tumor response in locally advanced breast carcinomas treated with anthracyclin-based neoadjuvant chemotherapy.
    Patel T; Gupta A; Shah M
    J Cancer Res Ther; 2013; 9(2):245-9. PubMed ID: 23771367
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Value of 18F-FDG PET/CT Imaging Combined With Pretherapeutic Ki67 for Early Prediction of Pathologic Response After Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer.
    Luo J; Zhou Z; Yang Z; Chen X; Cheng J; Shao Z; Guo X; Tuan J; Fu X; Yu X
    Medicine (Baltimore); 2016 Feb; 95(8):e2914. PubMed ID: 26937935
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ER, PgR, HER-2, Ki-67, topoisomerase IIα, and nm23-H1 proteins expression as predictors of pathological complete response to neoadjuvant chemotherapy for locally advanced breast cancer.
    Li XR; Liu M; Zhang YJ; Wang JD; Zheng YQ; Li J; Ma B; Song X
    Med Oncol; 2011 Dec; 28 Suppl 1():S48-54. PubMed ID: 20872186
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of ER, PgR, HER-2, Ki-67, cyclin D1, and nm23-H1 as predictors of pathological complete response to neoadjuvant chemotherapy for locally advanced breast cancer.
    Li XR; Liu M; Zhang YJ; Wang JD; Zheng YQ; Li J; Ma B; Song X
    Med Oncol; 2011 Dec; 28 Suppl 1():S31-8. PubMed ID: 20844986
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High HER2/Centromeric Probe for Chromosome 17 Fluorescence In Situ Hybridization Ratio Predicts Pathologic Complete Response and Survival Outcome in Patients Receiving Neoadjuvant Systemic Therapy With Trastuzumab for HER2-Overexpressing Locally Advanced Breast Cancer.
    Kogawa T; Fouad TM; Liu DD; Wu J; Shen Y; Masuda H; Fujii T; Chavez-MacGregor M; Alvarez RH; Hortobágyi GN; Valero V; Ueno NT
    Oncologist; 2016 Jan; 21(1):21-7. PubMed ID: 26659222
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Multicenter Study of the Impact of Body Mass Index (BMI) on the incidence of Pathologic Complete Response (pCR) Among Saudi Patients with locally advanced Breast cancer (LABC) post Neoadjuvant Chemotherapy (NAC).
    Al-Saleh K; Abd El-Aziz N; Ali A; Abo Zeed W; Salah T; Elsamany S; Rasmy A; El Farargy O; Husain S; Al-Rikabi A; Alsaeed E; Aldiab A; Abd El-Warith A
    Gulf J Oncolog; 2019 May; 1(30):33-42. PubMed ID: 31242980
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monitoring Serum VEGF in Neoadjuvant Chemotherapy for Patients with Triple-Negative Breast Cancer: A New Strategy for Early Prediction of Treatment Response and Patient Survival.
    Wang RX; Chen S; Huang L; Zhou Y; Shao ZM
    Oncologist; 2019 Jun; 24(6):753-761. PubMed ID: 30126858
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of ER, PgR, HER-2, and Ki-67 in core biopsies and in definitive histological specimens in patients with locally advanced breast cancer treated with neoadjuvant chemotherapy.
    Rossi L; Verrico M; Tomao S; Ricci F; Fontana A; Spinelli GP; Colonna M; Vici P; Tomao F
    Cancer Chemother Pharmacol; 2020 Jan; 85(1):105-111. PubMed ID: 31754747
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinicopathological features of early failure of neoadjuvant chemotherapy in locally advanced breast cancer.
    Choi MK; Park YH; Kil WH; Lee JE; Nam SJ; Ahn JS; Im YH
    Cancer Chemother Pharmacol; 2014 Sep; 74(3):521-9. PubMed ID: 25047725
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ki-67 as a controversial predictive and prognostic marker in breast cancer patients treated with neoadjuvant chemotherapy.
    Ács B; Zámbó V; Vízkeleti L; Szász AM; Madaras L; Szentmártoni G; Tőkés T; Molnár BÁ; Molnár IA; Vári-Kakas S; Kulka J; Tőkés AM
    Diagn Pathol; 2017 Feb; 12(1):20. PubMed ID: 28222768
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-world data on breast pathologic complete response and disease-free survival after neoadjuvant chemotherapy for hormone receptor-positive, human epidermal growth factor receptor-2-negative breast cancer: a multicenter, retrospective study in China.
    Guan D; Jie Q; Wu Y; Xu Y; Hong W; Meng X
    World J Surg Oncol; 2022 Sep; 20(1):326. PubMed ID: 36175898
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.